FDA Approves First Nasal Spray For Treatment Of Anaphylaxis; Approved neffy (Epinephrine Nasal Spray) For Emergency Treatment Of Allergic Reactions (Type I)
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved neffy, the first nasal spray for the treatment of anaphylaxis, which is an emergency treatment for severe allergic reactions (Type I).
August 09, 2024 | 3:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The FDA's approval of neffy, the first nasal spray for treating anaphylaxis, is a significant milestone for the company. This approval could lead to increased market share and revenue growth.
The approval of neffy by the FDA is a significant achievement for SPRY. This new product could capture a substantial market share in the emergency treatment of severe allergic reactions, leading to potential revenue growth and a positive impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100